Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Amgen, Inc.
EIR
•Amgen, Inc.•December 13, 2019

Amgen, Inc. – FDA EIR, Dec 13, 2019

Record Details

A routine FDA Current Good Manufacturing Practice (cGMP) inspection of Amgen, Inc.'s Thousand Oaks, California facility took place from December 9-13, 2019. This surveillance inspection, conducted under CPGM 7356.002M, focused on four licensed biological drug substances: epoetin alfa (Epogen), erenumab (Aimovig), adalimumab-atto (AMJEVITA), and bevacizumab-awwb (MVASI). The inspection culminated in a single FDA Form 483 observation. The primary issue was that procedures for equipment cleaning and maintenance were deficient, specifically regarding the lack of demonstrated disinfection efficacy after microbiological excursions (e.g., mold) were found in controlled areas, failing to verify cleanliness immediately before use. This was referenced under 21 CFR 211.67(b)(6). Further discussions with management highlighted several concerns: a lack of comprehensive training for quality control and quality assurance staff on specialized topics like elemental impurity testing, an inadequate elemental impurity testing plan that only covered drug product batches and not drug substances, and the absence of a structured program for deep cleaning and inspection of heavy equipment areas. Amgen committed to implementing corrections, including more frequent and thorough cleaning, enhanced environmental monitoring, and improved training across all relevant sites. No samples were collected, and no refusals were documented during the inspection.

Company
Amgen, Inc.
Inspection date
December 13, 2019
Product type
Biologics
Office
Los Angeles District Office
People
  • Aine Hanly (company_representative)
  • Joe Beaty (company_representative)
  • Richard O"Keeffe (recipient)
  • Roger F. Zabinski (Investigator)
  • Ernest Donkor (company_representative)
View Company Profile

ID · 7155ec06-4efb-4490-8b2d-eecd030871d1

Violation Codes1
21 CFR 211.67(b)(6)

Full citation text and observation details available on the Dashboard.

Other documents for Amgen, Inc.
  • 483 - 2025-03-13March 13, 2025
  • 483 - 2024-02-06February 6, 2024
  • 483 - 2019-12-13December 13, 2019
  • 483 - 2017-05-16May 16, 2017
  • WARNING_LETTER - 2013-06-17June 17, 2013

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Amgen, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.